We recently observed a striking increase in multidrug-resistant tuberculosis (MDR-TB) among patients admitted to the Chest Service at Bellevue Hospital Center in New York. We reviewed the laboratory susceptibility test results of 4681 tuberculosis (TB) cases over the past 20 years. Combined resistance to isoniazid and rifampin increased from 2.5% in 1971 to 16% in 1991 with higher rates noted for individual drugs. We reviewed the medical records of 100 patients with drug-resistant TB, finding that these individuals were predominantly less than 40 years of age, minority, male, jobless, undomiciled, with a high percentage of drug abuse and human immunodeficiency virus infection. We conclude that the epidemics of AIDS and TB are complicated by a third epidemic of MDR-TB. This third epidemic requires urgent attention to achieve more rapid diagnosis, to develop new therapeutic regimens, and to address the social and hospital environment to care for these individuals. (Chest 1994;105:45-8) 
One disease -three epidemics THE FIRST EPIDEMIC: A GLOBAL RESURGENCE
The world faces three epidemics from tuberculosis. The first of these is the re-emergence of tuberculosis itself. Before 1985 the industrialised world had experienced a steady decline in tuberculosis.'2 There had also been some success of tuberculosis control in the developing world with a decline in incidence in some countries and a stabilisation in others,3 albeit often at an unsatisfactory level. Overall, the pattern of events looked promising. Funding for control programmes in affluent countries was reduced, research interest waned, and it was believed that, like smallpox, this disease could be eventually eradicated.2 However, the disease has returned with a vengeance. In 1992 the World Health Organisation (WHO) declared tuberculosis a "global emergency". It estimated that 1-7 billion people were latently infected with Mycobacterium tuberculosis (approximately one third of the world's population), with an annual toll of eight million new cases of active disease and 2-9 million deaths. Thus, tuberculosis represents the single biggest killer of all the infectious diseases and accounts for 26% of avoidable adult deaths in the developing world.
THE SECOND EPIDEMIC: HIV AND TUBERCULOSIS
Co-infection with HIV and tuberculosis is a "cruel duet", each exacerbating the other and resulting in a rapid progression of early HIV infection and spread of tuberculosis into the non-HIV infected population .4 This second epidemic of HIV-related tuberculosis has been termed the "new tuberculosis"5 and bears only a resemblance to its older sibling. The major differences are shown in the box. For example, pulmonary disease may present with non-specific features including radiographic bilateral lower zone shadowing, a loss of predilection for the upper lobes, and absence of cavities. Extrapulmonary tuberculosis, particularly disseminated disease, is more frequent. The age of presentation has shifted away from those previously most at risk -the very young and elderly -to young adults who account for those most economically productive. Of all the risk factors for the development of tuberculosis, HIV is by far the most potent with a relative risk of 6-100 when Impact of HIV on tuberculosis
Increase in reactivation of old latent infection
Increase in reinfection and recurrent disease following treatment Loss of disease control in poor communities Change in the clinical picture (increase in extrapulmonary and disseminated disease) Change in age of presentation (increase in young adults)
Marked increase in mortality compared with HIV negative individuals.6 Not surprisingly, Africa is experiencing a major resurgence in tuberculosis, mainly as a consequence of the overlap between high levels of latent tuberculosis infection and a very high level of HIV infection, 20-67% of tuberculosis patients being co-infected with HIV.7 In one large necroscopic study in Abidjan, Cote d'Ivoire, tuberculosis was found in over 50% of cadavers with AIDS-defining pathology.8 Particularly worrying is the fact that only one tenth of the world's tuberculosis infected population reside in Africa; a further billion live in Asia and the western Pacific. As HIV spreads into these countries, the potential outcome is devastating.
THE THIRD EPIDEMIC: MULTIDRUG RESISTANCE
The third epidemic is in our midst -namely, multidrugresistant tuberculosis. To date, the brunt of the epidemic has been confined to the USA,9-'3 but the conditions that gave rise to multidrug-resistant tuberculosis exist throughout the world and we would be wise to learn from their experience. Of the US cities affected, New York has been particularly badly hit. This picture is well exemplified in the introductory article -a hospital-based study by Neville Earlier this century, before antituberculous chemotherapy, tuberculosis was decreasing in the industrialised world as a result of social and economic changes -for example, data from army recruits in the Netherlands suggested an annual rate of decline of 5-6%. This improved to 10% with the introduction of effective drugs. Similar trends have been noted in US naval recruits up to the mid 1980s. The resurgence in tuberculosis in industrialised countries has been ascribed to:
(1) immigration of a foreign population who are at high risk of developing disease, (2) coinfection with HIV, (3) an increase in specific high risk groups such as intravenous drug users, and (4) "other factors" not attributable to the above. Bloom and Murray analysed the relative contribution of such factors in the USA and showed that the increase cannot be entirely explained by the first three.' They concluded that the resurgence is also due in part, to increasing poverty and, in particular, a failing tuberculosis programme infrastructure. All of these factors are present in a handful of US cities. New York exemplifies the plight of the urban poor leaving most of the country left relatively unscathed. This problem is depicted in the figure, which shows a doubling in tuberculosis case rates in New York but stability throughout the USA.
Techniques in molecular epidemiology (described on the next page) support this view. DNA fingerprinting has been used to distinguish new infections from reactivation (see box). Cluster The Neville study raises wider issues associated with the surveillance of multidrug-resistant tuberculosis: (1) to what extent are these data skewed in favour of drug resistant cases (those with multidrug-resistant disease may circulate through several centres); (2) the data do not distinguish primary from acquired resistance; (3) Another study used RFLP analysis on isolates from 130 unselected tuberculosis patients over a three year period from a large hospital in the Bronx. Over a third of these cases showed clustering indicative of recent transmission. Independent risk factor analysis demonstrated that drug resistance was 4-5 times more likely in clustered groups (p<0OO5).24 These studies and others'928 have clearly shown clustering of newly transmitted cases with primary drug-resistant tuberculosis. Moreover, it is likely that many patients and health care workers were infected (as defined by skin test conversion) with multidrug-resistant tuberculosis."3'9 In most cases, guidelines for the management of cases of smear positive tuberculosis were not followed.'2"'39 Solutions What lessons can be learnt from the USA? HIV infection, drug misuse, poverty, and homelessness constitute key risk factors in the transmission of multidrugresistant tuberculosis. However, it is unlikely that we will be able to impinge upon these, at least in the near future. Intervention with alternative drugs that are presently available is unlikely to yield better results. In centres of excellence the cure rate for multidrug-resistant tuberculosis is hardly better than if the patient had received no treatment. ' When an appropriate regimen is taken, more than 95% of organisms are killed within the first few weeks of therapy. However, a further prolonged period of treatment (at least a total of six months) is required to eradicate metabolically inactive persister bacilli. The patient usually feels well within a few weeks oftreatment, thus making further adherence to therapy particularly difficult. Compliance and cure rates have been highest with short-course chemotherapy (six months)'2' and when patients have been in hospital or have received directly observed therapy. 112230-2 Hospitalisation may be reasonable for the period when the patient is infectious; beyond this, it is both expensive and enforced incarceration is ethically dubious. For most cases good compliance can be achieved using directly observed therapy.
DIRECTLY OBSERVED THERAPY AND INTERMITTENT TREATMENT
Drug compliance can be vastly improved if the patient is directly observed to take the medication. Excellent drug completion rates and high cure rates have been reported using directly observed therapy both in industrialised2232 and developing'03' countries. A protocol for directly observed therapy employed in Denver, Colorado, used two weeks of daily therapy followed by 24 weeks of twice weekly intermittent therapy.22 Less than 10% of participants were lost to follow up. The added expense of the time of health care workers is compensated by savings from reduction in drug use and investigations (monitoring can be less rigorous with directly observed therapy). Moreover, the potential savings from eliminating new drug resistance is huge. Al outlined by the CDC'5 and elsewhere.' It is a mistake just to add another drug when a patient is not responding clinically, as this will increase the catalogue of drugs to which resistance is acquired. Where multidrug-resistant tuberculosis is suspected, the patient should be started on five or six drugs. When results of susceptibility testing are available, at least three drugs to which the strain is susceptible should be continued for up to 24 months, depending on the severity of resistance. Iseman has reviewed the treatment of multidrug-resistant tuberculosis and suggests several regimens for patients with LEARNING POINTS * The incidence of multidrug-resistant tuberculosis is increasing rapidly in underprivileged, uncompliant, minority groups in developed countries in whom it is often fatal. * Multidrug-resistant tuberculosis already poses an additional and serious threat to those in close contact through social and health care occupations. * As worldwide trends continue towards increasing incidence of tuberculosis and HIV infection, the problem from multidrug-resistant disease is likely to increase and to pose a future threat to all communities. * It is largely a consequence of recent failings in the infrastructure of tuberculosis control, and of inappropriate treatment in poorly compliant subjects. * Its control will require rigorous control of tuberculosis itself, using novel strategies in the poorly compliant so that the continued emergence of multidrug-resistant organisms is minimised.
* The development of new drugs offers less hope of an immediate solution. * The use of newly developed molecular techniques will improve rapid recognition of multidrug-resistant tuberculosis so that delay in appropriate treatment with multiple drugs may be minimised. 
